Structural Biology and Fragment-Based Drug Discovery Outsourcing Services CRO

Company & business model

SARomics Biostructures is a research-intensive contract research organization (CRO) in Lund, Sweden. SARomics Biostructures provides a broad range of structural biology outsourcing services, including protein crystallization and X-ray crystallography, structure characterization of antibody-antigen complexes and biosimilars, protein NMR spectroscopy, fragment-based drug discovery, and computational chemistry. In addition, SARomics offers the proprietary Weak Affinity Chromatography (WAC™) technology for fragment screening in collaboration with our partner Red Glead Discovery. Our labs and company management are located in Lund at Medicon Village.

The company was founded in 2006 and quickly established itself as a premium provider of structural biology and drug discovery outsourcing services to small- and medium-sized biotech companies, large pharma, and academic groups from North and South America, Asia, Europe, Scandinavia, and Australia. During the 17 years of our existence, we have contributed to various projects within all areas of structural biology and structure-based drug discovery and design. This is well documented in many
publications, which we had the privilege to co-author with some of our customers. The scope of these publications reflects the broad experience we have gathered throughout the years serving the structural biology and drug discovery community. However, we do not claim any ownership of customers' projects.

Our services are provided on a fee-for-service basis with a project-based payment schedule, which includes a startup fee and additional milestone-based payments. FTE-based payment may also be applied upon agreement with the customer.

Why choose SARomics Biostructures?

By serving large pharma and biotech companies worldwide for more than 17 years, the SARomics Biostructures team has established a proven track record of success and has gathered extensive experience in all aspects of structural biology and structure-based drug design. Each year on average, we work with over 100 structural biology and early-stage drug discovery projects. Since 2006 more than 500 disclosable protein structures have been submitted to the PDB, and our staff has contributed to many structural papers published in leading journals like Nature, Nature Commun., Eur. J. Med. Chem., J. Biol. Chem, J. Synchrotron Rad., Sci. Rep., PNAS, J. Med. Chem., FASEB J., JACS, etc.

After a discussion with marketing experts and some clients, in a recent blog post, we summarized the benefits of working with us:
  • Our clients get swift replies to contact requests and realistic project timelines
  • Our client's projects are handled by a company with a strong brand identity
  • We guarantee our clients high quality services
  • Our clients meet a team of highly experienced and service-minded professionals
  • Projects are run at a robust technology platform with a wide variety of structural biology experimental methods
  • Our clients can benefit from a unique proprietary method for compound screening
  • We enjoy a high degree of customer satisfaction
  • We enjoy an intellectually rich environment at Medicon Village, located close to the MAX IV synchrotron facility
We strongly believe that our services are truly among the most competitive on the market!

See our 2024 presentation of the company services and case studies